Abstract
A QSAR study is reported to predict the binding affinity of a set of 81 modulators for both of human estrogen receptor α and β (ERα and ERβ). In this study, the derived QSAR models were built by forward stepwise multilinear regression (MLR) and nonlinear radial basis function neural networks (RBFNN), respectively. The statistical characteristics of the external test set provided by multiple linear model (R2=0.814, F=61.277, RMS=0.5461 for ERα; R2=0.600, F=21.039, RMS=0.6707 for ERβ) indicated satisfactory stability and predictive ability of the model built. The predictive ability for ERβ of RBFNN model is somewhat superior: R2=0.7691, F=32.012, RMS=0.5764, and the similar result was obtained for ERα of the test set: R2=0.7950, F=54.131 RMS=0.3120. Overall, the appropriate results proved the models to be meaningful and useful to predict and virtual screen of the derivatives with high binding activity.
Keywords: Quantitative Structure-Activity Relationships (QSAR), hERα, hERβ, Multiple Linear Regression (MLR), Radial Basis Function Neural Networks (RBFNN), Binding activity.
Letters in Drug Design & Discovery
Title:Prediction of the Estrogen Receptor Binding Affinity for both hERα and hERβ by QSAR Approaches
Volume: 11 Issue: 3
Author(s): Changliang Deng, Xuanxuan Chen, Hongying Lu, Xin Yang, Feng Luan and Maria Natalia Dias Soeiro Cordeiro
Affiliation:
Keywords: Quantitative Structure-Activity Relationships (QSAR), hERα, hERβ, Multiple Linear Regression (MLR), Radial Basis Function Neural Networks (RBFNN), Binding activity.
Abstract: A QSAR study is reported to predict the binding affinity of a set of 81 modulators for both of human estrogen receptor α and β (ERα and ERβ). In this study, the derived QSAR models were built by forward stepwise multilinear regression (MLR) and nonlinear radial basis function neural networks (RBFNN), respectively. The statistical characteristics of the external test set provided by multiple linear model (R2=0.814, F=61.277, RMS=0.5461 for ERα; R2=0.600, F=21.039, RMS=0.6707 for ERβ) indicated satisfactory stability and predictive ability of the model built. The predictive ability for ERβ of RBFNN model is somewhat superior: R2=0.7691, F=32.012, RMS=0.5764, and the similar result was obtained for ERα of the test set: R2=0.7950, F=54.131 RMS=0.3120. Overall, the appropriate results proved the models to be meaningful and useful to predict and virtual screen of the derivatives with high binding activity.
Export Options
About this article
Cite this article as:
Deng Changliang, Chen Xuanxuan, Lu Hongying, Yang Xin, Luan Feng and Cordeiro Natalia Dias Soeiro Maria, Prediction of the Estrogen Receptor Binding Affinity for both hERα and hERβ by QSAR Approaches, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113109990067
DOI https://dx.doi.org/10.2174/15701808113109990067 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Application of Immunological Techniques (from Vaccination to Final Measurements) in Determination of Pharmaceutical Residues in Environmental Samples
Current Analytical Chemistry C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition
Current Drug Metabolism Recent Patents on New Steroid Agents Targeting the Steroidogenesis for Endocrine Cancer Treatments
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant
Mini-Reviews in Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421
Anti-Cancer Agents in Medicinal Chemistry Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Editorial (Hot Topic: Pharmacological and Molecular Targets in Cellular Redox Status Maintenance)
Current Pharmaceutical Design Human Growth Hormone Induced Cholestatic Hepatitis in a Growth Hormone Deficient Patient with Short Stature
Current Drug Safety Patent Selections
Recent Patents on Biomarkers Nanoparticle Therapy for Allergic and Inflammatory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Letters in Drug Design & Discovery